LIMN

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Liminatus Pharma, Inc. Class A Common Stock

NASDAQ | LIMN

1.41

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$145.16M

Market Cap

-

P/E Ratio

-0.16

EPS

$33.65

52 Week High

$1.12

52 Week Low

HEALTHCARE

Sector

LIMN Chart

Recent Chart
Price Action

LIMN Technicals

Tags:

LIMN Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (None)
Gross Profit -
Total Revenue -
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$2.9M
Selling General And Administrative -
Research And Development -
Operating Expenses $2.9M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense $138K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$2.9M
Income Tax Expense $19K
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -
Ebitda -$2.7M
Net Income -$2.9M

Revenue & Profitability

Earnings Performance

LIMN Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (None)
Total Assets $2.8M
Total Current Assets $813K
Cash And Cash Equivalents At Carrying Value $805K
Cash And Short Term Investments $805K
Inventory -
Current Net Receivables $6.5K
Total Non Current Assets $2M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.7K
Other Non Current Assets -
Total Liabilities $19M
Total Current Liabilities $8.7M
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt $5.1M
Total Non Current Liabilities $10M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $5.1M
Other Current Liabilities $3.6M
Other Non Current Liabilities -
Total Shareholder Equity -$16M
Treasury Stock -
Retained Earnings -$18M
Common Stock $1.8M
Common Stock Shares Outstanding $7.2M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (None)
Operating Cashflow -$3.1M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $2M
Cashflow From Financing $1M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$1.8M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$2.9M

yearly Income Statement (As of Dec 31, 2024)

Field Value (None)
Gross Profit -
Total Revenue -
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$2.9M
Selling General And Administrative -
Research And Development -
Operating Expenses $2.9M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense $138K
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax -$2.9M
Income Tax Expense $19K
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -
Ebitda -$2.7M
Net Income -$2.9M

LIMN News

LIMN Profile

Liminatus Pharma, Inc. Class A Common Stock Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies aimed at treating various forms of cancer. Based in La Palma, California, the company leverages innovative science and technology to advance its therapeutic pipeline, targeting unmet medical needs in oncology. With a strategic approach to clinical development, Liminatus is positioned to contribute significantly to the evolving landscape of cancer treatment, making it a noteworthy entity for institutional investors in the biotech sector.

VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+118.14%
$9.07
BITF
+28.33%
$5.39
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BYND
-48.50%
$1.03
IONZ
-35.04%
$2.21
NVTS
+23.51%
$10.16
JOBY
+2.94%
$16.76
ETHD
+16.10%
$3.82
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
SNAP
-7.15%
$7.78
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
RR
-9.34%
$5.92
TLRY
-1.74%
$1.69
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
SOUN
+10.25%
$19.14
RXRX
+4.41%
$5.55
ONDS
+17.24%
$10.81
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
VALE
-2.53%
$10.75
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
PFE
-0.30%
$24.70
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
IREN
+8.04%
$64.58
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
XCH
+103.41%
$1.68
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
TMQ
-9.46%
$5.93
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
WWR
0.00%
$1.98
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
OKLO
+16.20%
$171.00
HOOD
+1.03%
$140.40
PMAX
+44.78%
$3.75
HPE
+2.76%
$25.07
VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+118.14%
$9.07
BITF
+28.33%
$5.39
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BYND
-48.50%
$1.03
IONZ
-35.04%
$2.21
NVTS
+23.51%
$10.16
JOBY
+2.94%
$16.76
ETHD
+16.10%
$3.82
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
SNAP
-7.15%
$7.78
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
RR
-9.34%
$5.92
TLRY
-1.74%
$1.69
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
SOUN
+10.25%
$19.14
RXRX
+4.41%
$5.55
ONDS
+17.24%
$10.81
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
VALE
-2.53%
$10.75
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
USAR
+17.01%
$38.15
DFLI
+41.35%
$1.54
PFE
-0.30%
$24.70
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
NAK
+26.47%
$2.56
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
IREN
+8.04%
$64.58
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
XCH
+103.41%
$1.68
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
TMQ
-9.46%
$5.93
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
WWR
0.00%
$1.98
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
OKLO
+16.20%
$171.00
HOOD
+1.03%
$140.40
PMAX
+44.78%
$3.75
HPE
+2.76%
$25.07
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.